

Special Issue

Advances in Vaccine Development and Immunotherapies

Message from the Guest Editors

During Covid-19 pandemic, it is very important to submit reports on vaccine development. Vaccine development can include vaccines against viral diseases, dendritic cell vaccines against cancer or other diseases. In addition, this issue can involve recent development of new immunotherapies against cancer such as chimeric antigen receptor (CAR) T cells therapies, checkpoint inhibitors, monoclonal antibodies, bi-specific antibodies, and combination therapies. The reports on pre-clinical vaccine development, clinical trial data and reviews can be submitted to this issue.

Guest Editors

Dr. Vita Golubovskaya

1. Promab Biotechnologies, 2600 Hilltop Drive, Building B, C348, Richmond, CA 94803, USA

2. Department of Medicine, University of Oklahoma Health Sciences Center, Andrews Academic Tower, 800 Stanton L. Young Blvd, Oklahoma City, OK 73104, USA

Dr. Emmanuel Datan

Vascular Program, Institute for Cell Engineering and Department of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Deadline for manuscript submissions

closed (10 March 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/56026

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).